Patient demographics and baseline characteristics
| Tofacitinib 5 mg two times a day N=1194 | Tofacitinib 10 mg two times a day N=1197 | Placebo N=670 | ||||||||||
| Anti-CCP+/RF+ N=776 | Anti-CCP+/RF- N=136 | Anti-CCP-/RF+ N=74 | Anti-CCP-/RF- N=208 | Anti-CCP+/RF+ N=775 | Anti-CCP+/RF- N=113 | Anti-CCP-/RF+ N=68 | Anti-CCP-/RF- N=241 | Anti-CCP+/RF+ N=410 | Anti-CCP+/RF- N=88 | Anti-CCP-/RF+ N=40 | Anti-CCP-/RF- N=132 | |
| Median age, years (range) | 54.0 (20.0–86.0) | 53.0 (20.0–82.0) | 53.0 (25.0–79.0) | 53.0 (18.0–83.0) | 54.0 (18.0–85.0) | 54.0 (20.0–78.0) | 53.0 (28.0–76.0) | 54.0 (19.0–78.0) | 54.0 (18.0–82.0) | 47.5 (18.0–80.0) | 52.5 (34.0–74.0) | 53.0 (29.0–79.0) |
| Female, n (%)* | 651 (83.9) | 120 (88.2) | 62 (83.8) | 177 (85.1) | 650 (83.9) | 99 (87.6) | 62 (91.2) | 205 (85.1) | 326 (79.5) | 74 (84.1) | 34 (85.0) | 109 (82.6) |
| Smoking status, n (%)* | ||||||||||||
| Never smoked | 492 (63.4) | 107 (78.7) | 52 (70.3) | 144 (69.2) | 485 (62.6) | 87 (77.0) | 48 (70.6) | 175 (72.6) | 252 (61.6) | 59 (67.8) | 26 (65.0) | 81 (61.4) |
| Smoker | 114 (14.7) | 11 (8.1) | 9 (12.2) | 28 (13.5) | 153 (19.7) | 8 (7.1) | 11 (16.2) | 39 (16.2) | 79 (19.3) | 13 (14.9) | 10 (25.0) | 25 (18.9) |
| Ex-smoker | 170 (21.9) | 18 (13.2) | 13 (17.6) | 36 (17.3) | 137 (17.7) | 18 (15.9) | 9 (13.2) | 27 (11.2) | 78 (19.1) | 15 (17.2) | 4 (10.0) | 26 (19.7) |
| BMI mean (range) | 26.6 (14.3–70.3) | 26.0 (17.5–49.7) | 27.7 (16.7–52.1) | 29.2 (16.0–70.8) | 26.8 (14.4–55.6) | 25.8 (15.6–44.4) | 28.1 (16.3–58.1) | 28.4 (17.1–50.2) | 26.9 (16.0–55.1) | 25.1 (15.4–50.4) | 28.3 (17.5–45.9) | 29.5 (14.7–53.8) |
| Duration of RA, years, mean (SD) | 9.4 (8.0) | 9.3 (8.5) | 7.6 (7.4) | 6.7 (7.6) | 9.7 (8.3) | 8.4 (8.6) | 9.6 (8.4) | 7.6 (7.5) | 9.9 (8.6) | 6.6 (6.4) | 11.9 (8.4) | 8.4 (8.9) |
| DAS28-4(ESR), mean (SD) | 6.5 (1.0) | 6.2 (0.9) | 6.3 (0.9) | 6.5 (1.0) | 6.5 (1.0) | 6.1 (0.9) | 6.4 (1.0) | 6.4 (1.0) | 6.5 (0.9) | 6.1 (0.9) | 6.2 (1.1) | 6.4 (1.0) |
| HAQ-DI, mean (SD) | 1.5 (0.7) | 1.4 (0.6) | 1.4 (0.7) | 1.5 (0.6) | 1.5 (0.7) | 1.2 (0.6) | 1.4 (0.7) | 1.5 (0.6) | 1.5 (0.7) | 1.3 (0.7) | 1.4 (0.7) | 1.4 (0.6) |
*Percentages are based on patients with non-missing values.
BMI, body mass index; CCP, cyclic citrullinated peptide; DAS28-4(ESR), Disease Activity Score in 28 joints, erythrocyte sedimentation rate; HAQ‑DI, Health Assessment Questionnaire-Disability Index; RA, rheumatoid arthritis; RF, rheumatoid factor.